The Cancer News: Kaposi sarcoma in 2026: A disease controlled in the West, still devastating sub-Saharan Africa – European AIDS Treatment Group

The global management of Kaposi sarcoma (KS) has diverged into two starkly different realities by May 2026. While the disease has become largely controlled and manageable in Western healthcare systems, it continues to cause widespread devastation across sub-Saharan Africa.

This disparity is highlighted by reporting from the European AIDS Treatment Group (EATG), which emphasizes that the gap in outcomes is not a result of medical impossibility, but rather a failure of equitable access to diagnostics and antiretroviral therapy (ART).

Kaposi sarcoma is a systemic multicentric tumor caused by the human herpesvirus 8 (HHV-8). It typically manifests as purple, red, or brown lesions on the skin and mucous membranes, but it can also invade internal organs, including the lungs and gastrointestinal tract.

The Impact of Antiretroviral Therapy in the West

In North America and Europe, the prevalence of AIDS-related Kaposi sarcoma has declined significantly. This shift is primarily attributed to the widespread availability and efficacy of modern ART, which suppresses HIV viral loads and allows the immune system to recover.

When HIV is effectively managed, the immune system can often keep HHV-8 in check, preventing the onset of KS or leading to the regression of existing lesions without the need for aggressive chemotherapy.

For the minority of patients in the West who still develop severe KS, access to targeted chemotherapy, such as liposomal doxorubicin, provides a high degree of control over the disease, transforming it from a terminal diagnosis into a manageable chronic condition.

The Crisis in Sub-Saharan Africa

In contrast, sub-Saharan Africa continues to face a heavy burden of both HIV-associated and endemic Kaposi sarcoma. The disease often presents at advanced stages, where lesions have already compromised respiratory or digestive functions.

Several systemic factors contribute to these poor outcomes:

• Limited access to early diagnostic screening and biopsy tools.
• High costs and supply chain instability for second- and third-line ART.
• Lack of affordable, specialized oncology care for severe systemic KS.
• The prevalence of endemic KS, which occurs in individuals without HIV and is often slower-progressing but still difficult to treat in resource-poor settings.

The EATG notes that while the medical community possesses the tools to control the disease, the infrastructure required to deliver these interventions is often absent or underfunded in the regions that need them most.

Medical and Public Health Context

The biological driver of KS, HHV-8, behaves differently depending on the host’s immune status. In the context of severe immunosuppression, the virus triggers the proliferation of blood vessel cells, leading to the characteristic lesions of the disease.

Public health experts distinguish between several forms of the disease:

• Epidemic KS: Closely linked to the HIV/AIDS pandemic.
• Endemic KS: Found primarily in Africa, occurring in both HIV-positive and HIV-negative individuals.
• Classic KS: A rare form typically seen in elderly men of Mediterranean or Eastern European descent.
• Iatrogenic KS: Occurring in patients who have received organ transplants or other immunosuppressive drugs.

The persistence of endemic KS in sub-Saharan Africa suggests that HHV-8 is deeply embedded in certain populations, complicating the effort to eradicate the disease through HIV treatment alone.

Future Requirements for Global Equity

Addressing the disparity in KS outcomes requires a shift from treating the disease as a rare oncology case to managing it as a critical public health priority in Africa.

Medical advocates argue for the decentralization of KS care, moving diagnosis and treatment from major urban hospitals to rural clinics. This would allow for earlier intervention and better adherence to ART, which remains the most effective way to prevent the progression of HIV-associated KS.

the development of a vaccine for HHV-8 remains a long-term goal for researchers, as such a tool would provide a preventative measure that does not rely on the continuous availability of expensive medication.

Until such breakthroughs occur, the EATG and other global health bodies emphasize that the current survival gap is a matter of policy and funding rather than a lack of scientific knowledge.